DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Hsp90 inhibitor
Hsp90 inhibitor
C-Terminal HSP90 Inhibitors Block the HSP90:HIF-1Α Interaction and Inhibit the Cellular Hypoxic Response
Hsp90 Inhibitor As a Sensitizer of Cancer Cells to Different Therapies (Review)
Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors
The Hsp90 Chaperone Network Modulates Candida Virulence Traits
Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia
A Novel Hsp90 Inhibitor Activates Compensatory Heat Shock Protein Responses and Autophagy and Alleviates Mutant A53T A-Synuclein Toxicity S
HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells
HSP90 Inhibitor AUY922 Induces Cell Death by Disruption of the Bcr-Abl, Jak2 and HSP90 Signaling Network Complex in Leukemia Cells
The Hsp90 Inhibitor Geldanamycin Selectively Sensitizes Bcr-Abl
A NOVEL HSP90 INHIBITOR to DISRUPT HSP90/P50cdc37 COMPLEX for PANCREATIC CANCER THERAPY
Heat Shock Protein 90 Chaperones E1A Early Protein of Adenovirus 5 and Is Essential for Replication of the Virus
BIIB021, an Hsp90 Inhibitor: a Promising Therapeutic Strategy for Blood Malignancies (Review)
Targeting the Hsp90-Cdc37-Client Protein Interaction to Disrupt Hsp90 Chaperone Machinery Ting Li1, Hu-Lin Jiang2, Yun-Guang Tong3,4 and Jin-Jian Lu1*
Geldanamycin, a Ligand of Heat Shock Protein 90, Inhibits Herpes Simplex Virus Type 2 Replication Both in Vitro and in Vivo
Heat Shock Protein 90 and Role of Its Chemical Inhibitors in Treatment of Hematologic Malignancies
Hsp90 Inhibitors Enhance the Antitumoral Effect of Osimertinib in Parental and Osimertinib-Resistant Non-Small Cell Lung Cancer Cell Lines
Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile
Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Top View
Blocking Heat Shock Protein-90 Inhibits the Invasive Properties and Hepatic Growth of Human Colon Cancer Cells and Improves
Mechanisms of Resistance to Hsp90 Inhibitor Drugs: a Complex Mosaic Emerges
Heat Shock Protein 90 (Hsp90)-Inhibitor-Luminespib-Loaded- Protein-Based Nanoformulation for Cancer Therapy
Overcoming Acquired Resistance to HSP90 Inhibition by Targeting JAK-STAT Signalling in Triple-Negative Breast Cancer Nuramalina H
Hsp90 Inhibition As a Means to Inhibit Activation of the NLRP3
HSP-90 Inhibitor Ganetespib Is Synergistic with Doxorubicin in Small Cell Lung Cancer
Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy
HSP90 Inhibitor NVP-BEP800 Affects Stability of SRC Kinases and Growth
HSP90 Inhibitors for High-Grade Glioma Treatment
A Novel Hsp90 Inhibitor to Disrupt Hsp90/Cdc37 Complex Against Pancreatic Cancer Cells
Synergism Between Etoposide and 17-AAG In
A Novel Hsp90 Inhibitor to Disrupt Hsp90/Cdc37 Complex Against Pancreatic Cancer Cells
Pharmaceuticals
The Heat Shock Protein 90 Inhibitor SNX-2112 Inhibits B16 Melanoma Cell Growth in Vitro and in Vivo
The Sensitivity to Hsp90 Inhibitors of Both Normal and Oncogenically Transformed Cells Is Determined by the Equilibrium Between
Molecular Basis for the Actions of Hsp90 Inhibitors and Cancer Therapy
A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors Or Soft-Tissue Sarcomas
Investigation of the Novel Small Molecule HSP90 Inhibitor, NXD30001, in a Mouse Model of Amyotrophic Lateral Sclerosis
Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with Respect to Bcr-Abl Status and Imatinib Mesylate Sensitivity
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Phase I and Pharmacological Study of Cytarabine and Tanespimycin in Relapsed and Refractory Acute Leukemia
The HSP90 Inhibitor, AUY-922, Ameliorates the Development of Nitrogen Mustard-Induced Pulmonary Fibrosis and Lung Dysfunction in Mice
Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF
Inhibition of Heat Shock Proteins HSP90 and HSP70 Induce
The HSP90 Inhibitor Ganetespib: a Potential Effective Agent for Acute
Small Molecule Inhibitors of HSF1-Activated Pathways As Potential Next-Generation Anticancer Therapeutics
(17-AAG) Synergizes with Cisplatin and Induces Apoptosis in Cisplatin-Resistant Esophageal Squamous Cell Carcinoma Cell Lines Via the Akt/XIAP Pathway
Novel HSP90-PI3K Dual Inhibitor Suppresses Melanoma Cell Proliferation by Interfering with HSP90-EGFR Interaction and Downstream Signaling Pathways
Inhibition of Cancer Invasion and Metastasis by Targeting the Molecular Chaperone Heat-Shock Protein 90
[email protected]
: an Emerging Hub of a Networker
Maximizing the Therapeutic Potential of HSP90 Inhibitors Lisa M
Interaction of Heat-Shock Protein 90B Isoform (Hsp90b) with Cellular Inhibitor of Apoptosis 1 (C-IAP1) Is Required for Cell Differentiation
Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia: Progress in a New Cancer Subtype
HSP90 Inhibitors in Lung Cancer: Promise Still Unfulfilled
An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration That Involves Lysyl Oxidase 2-Like Protein
17-AAG Mediated HSP90 Inhibition As an Effective Therapy for Lymphoma Stem Cells by Bryan W. Newman a Dissertation Submitted In
TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells